Anticancer Peptides PL-AC(Jiangsu Pulai Pharmaceutical Biotechnology)

N/A

Report date: 2023/11/16 10:59:43
NME

Base Information

Drug NameAnticancer Peptides PL-AC(Jiangsu Pulai Pharmaceutical Biotechnology)
Drug Alias Name抗癌肽PL-AC
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBradykinin B1 receptor antagonists
TargetsBradykinin B1 receptor
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPle Pharmacy (Jiangsu) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPle Pharmacy (Jiangsu) Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A